{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BSEP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BSEP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BSEP\",,,,,undefined,":{"symbol":"BSEP","market":"US","secType":"STK","nameCN":"Innovator U.S. Equity Buffer ETF - September","latestPrice":45.2495,"timestamp":1751486400000,"preClose":45.1341,"halted":0,"volume":6370,"delay":0,"floatShares":3650000,"shares":3650000,"eps":0,"marketStatus":"Pre-Mkt","change":0.1154,"latestTime":"07-03 08:45:23 EDT","open":45.15,"high":45.2495,"low":45.15,"amount":287804.7688,"amplitude":0.002205,"askPrice":53.71,"askSize":100,"bidPrice":37.33,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751549400000},"marketStatusCode":1,"adr":0,"exchange":"AMEX","adjPreClose":45.2495,"sharesOutstanding":3650000,"nav":45.14,"aum":164761000,"bidAskSpread":0,"volumeRatio":1.0774331171848581},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BSEP\",,,,,undefined,":{"symbol":"BSEP","floatShares":3650000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0774331171848581,"shares":3650000,"dividePrice":0,"high":45.2495,"amplitude":0.002205,"preClose":45.1341,"low":45.15,"week52Low":37.78,"pbRate":"--","week52High":45.2495,"institutionHeld":0,"latestPrice":45.2495,"eps":0,"divideRate":0,"volume":6370,"delay":0,"ttmEps":0,"open":45.15,"prevYearClose":42.9017,"prevWeekClose":44.9624,"prevMonthClose":45.1644,"prevQuarterClose":45.1644,"fiveDayClose":44.5391,"twentyDayClose":43.8025,"sixtyDayClose":38.8975},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BSEP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527216355","title":"Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527216355","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527216355?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:30","pubTimestamp":1744633800,"startTime":"0","endTime":"0","summary":"LIVMARLI Tablet formulation approved for patients with Alagille Syndrome  and Progressive Familial Intrahepatic Cholestasis . FOSTER CITY, Calif., April 14, 2025----Mirum Pharmaceuticals, Inc.  today announced that the U.S. Food and Drug Administration  has approved a new tablet formulation of LIVMARLI  for the treatment of cholestatic pruritus in patients with Alagille syndrome  and Progressive Familial Intrahepatic Cholestasis .\"The approval of LIVMARLI in tablet form provides a meaningful additional treatment option for patients with ALGS and PFIC. It allows flexibility for patients and physicians, with the liquid dosing used by the youngest patients and a convenient one-tablet per dose option for older patients,\" said Peter Radovich, president and chief operating officer at Mirum. \"We have had tremendous success with LIVMARLI since its launch and we hope that the availability of the tablet will provide convenience that positively impacts patients’ lives.\". LIVMARLI tablets are plan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-livmarli-now-fda-approved-123000969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4505","MIRM","PSC","X","BK4079","BSEP","BK4520","IBAT","BK4585","FSV","BK4006","BK4516","BK4532","ALGS","BK4139"],"gpt_icon":0},{"id":"2522301581","title":"LIVMARLI Now Approved in Japan for ALGS and PFIC","url":"https://stock-news.laohu8.com/highlight/detail?id=2522301581","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522301581?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:30","pubTimestamp":1743078600,"startTime":"0","endTime":"0","summary":"- LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan. FOSTER CITY, Calif., March 27, 2025----Mirum Pharmaceuticals, Inc.  today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI  oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome  and Progressive Familial Intrahepatic Cholestasis  in Japan.\"We are thrilled to see LIVMARLI approved as the first and only medication available in Japan for patients living with pruritus related to ALGS and PFIC,\" said Chris Peetz, chief executive officer at Mirum. \"Takeda is a leading global pharmaceutical company with demonstrated success in the development and commercialization of medicines for rare diseases. Under Takeda’s leadership, we are confident that LIVMARLI could have a meaningful imp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/livmarli-now-approved-japan-algs-123000577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["X","FSV","IBAT","BK4006","BK4588","BK4520","BSEP","BK4079","BK4585","MIRM","BK4139","BK4516","BK4505","PSC","ALGS","BK4532"],"gpt_icon":0},{"id":"2514898508","title":"Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514898508","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514898508?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:01","pubTimestamp":1740603660,"startTime":"0","endTime":"0","summary":"- 2025 expected global net product sales of $420 million to $435 million. - VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026. - CTEXLI  approved in the US for cerebrotendinous xanthomatosis. - Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET. FOSTER CITY, Calif., February 26, 2025----Mirum Pharmaceuticals, Inc.  today reported financial results for the fourth quarter and year-end 2024 and provided a business update.\"2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue,\" said Chris Peetz, chief executive officer of Mirum. \"We continue to expand the reach of our three commercial medicines within our patient communities and look forward to another year of strong financial performance. On top of this, we are looking forward to multiple upcoming clinical and regulatory milestones, such as PSC where we’re expecting ful","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-pharmaceuticals-reports-fourth-quarter-210100952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4520","BK4139","GGT","LU1878469433.USD","BK4585","FSV","BSEP","BK4079","BK4006","BK4599","BK4588","BK4516","ALT","IBAT","BK4532","FXS","PBC","BK4505","ALGS","MIRM","X","PSC"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BSEP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-11-19","symbol":"BSEP","amount":0.35968,"name":"BSEP","recordDate":"2019-11-21","payableDate":"2019-11-20","currency":"USD","type":"dividend","dateTimestamp":1574139600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BSEP\",market:\"US\",,,undefined,":[{"executeDate":"2019-11-19","recordDate":"2019-11-20","paymentDate":"2019-11-21","value":0.35968,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BSEP\",market:\"US\",delay:false,,,undefined,":{}}}